Advanced search
Publication Cover
Patient Preference and Adherence Volume 13, 2019 - Issue
Submit an article Journal homepage
149
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Two comparative assessments of intravenous immunoglobulin therapy switching patterns in the treatment of chronic inflammatory demyelinating polyneuropathy in the US

Jeffrey T Guptill1 Department of Neurology, Duke University, Durham, NC, USA
,
M Chris Runken2 Grifols SSNA, Research Triangle Park, Durham, NC, USACorrespondence[email protected]
,
Michael Eaddy3 Scientific Consulting, Xcenda, Palm Harbor, FL, USA
,
Orsolya E Lunacsek4 Real-World Evidence, Xcenda, Palm Harbor, FL, USA
,
Rupali M Fuldeore4 Real-World Evidence, Xcenda, Palm Harbor, FL, USA
,
Christopher M Blanchette5 Department of Public Health Sciences, University of North Carolina at Charlotte, Charlotte, NC, USA
,
Emily Zacherle5 Department of Public Health Sciences, University of North Carolina at Charlotte, Charlotte, NC, USA
&
Joshua M Noone5 Department of Public Health Sciences, University of North Carolina at Charlotte, Charlotte, NC, USA
 show all
Pages 649-655 | Published online: 30 Apr 2019

References

  • Gorson KC. An update on the management of chronic inflammatory demyelinating polyneuropathy. Ther Adv Neurol Disord. 2012;5(6):357–359. doi: 10.1177/1756285612457215.
  • Köller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med. 2005;352(13):1343–1356. doi: 10.1056/NEJMra04134715800230
  • Laughlin RS, Dyck PJ, Melton LJ, Leibson C, Ransom J, Dyck PJB. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology. 2009;73(1):39–45. doi: 10.1212/WNL.0b013e3181aaea47.19564582
  • Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2012;78(13):1009–1015. doi: 10.1212/WNL.0b013e31824de293.22454268
  • Joint task force of the European Federation of Neurological Societies and Peripheral Nerve Society. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – first revision. Eur J Neurol. 2010;17(3):356–363. doi:10.1111/j.1468-1331.2009.02930.x20456730
  • Abolhassani H, Asgardoon MH, Rezaei N, Hammarstrom L, Aghamohammadi A. Different brands of intravenous immunoglobulin for primary immunodeficiencies: how to choose the best option for the patient? Expert Rev Clin Immunol. 2015;11(11):1229–1243. doi:10.1586/1744666X.2015.107948526289377
  • Gelfand EW. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol. 2006;6(4):592–599. doi:10.1016/j.intimp.2005.11.00316504921
  • Hughes R AC, Donofrio P, Bri Vl, et al.; ICE Study Group. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7(2):136–144. doi: 10.1016/S1474-4422(07)70329-0.18178525

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.